Evidence map›Paper›PMID 30863309›Full record

ArticleFrontiers in pharmacology2019

Blocking α

Ludivine Boudieu, Sarah Mountadem, Amandine Lashermes, Mathieu Meleine, Lauriane Ulmann, François Rassendren, Youssef Aissouni, Benoit Sion, Frédéric Antonio Carvalho, Denis Ardid

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Evaluation ofACS chemical neuroscience · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ludivine BoudieuNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Sarah MountademNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Amandine LashermesNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Mathieu MeleineNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Lauriane UlmannIGF, CNRS, INSERM, Univ Montpellier, Montpellier, France.
François RassendrenIGF, CNRS, INSERM, Univ Montpellier, Montpellier, France.
Youssef AissouniNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Benoit SionNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Frédéric Antonio CarvalhoNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Denis ArdidNEURO-DOL, Université Clermont Auvergne, Clermont-Ferrand, France.
Inserm · FRCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder pain is frequently associated with bladder inflammation, as in conditions like interstitial cystitis (IC), for which current analgesic therapies have limited efficacy. The antinociceptive effect of alpha-2-delta (α

Indexed as

cystitis mouse modelinflammationNF-kB pathwaypainα2δ-1 ligands treatment

Identifiers

PMID30863309
PMCPMC6399165
OpenAlexW2915178896

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.